Transcatheter Treatment for Valve Insufficiency
CUSPA is developing the CUSPER®, an artificial cusp connected to a grasper that is attached to the native valve cusp/leaflet for aortic valve insufficiency (AI). Valve insufficiency is a heart disorder in which the valve does not close properly when the heart pumps out blood (mitral or tricuspid) or in the relaxation phase (aortic and pulmonary).
An estimated 20,000 patients in US annually would be suitable for an implantation of the CUSPER® product, indicating a total available annual market of over $0.5 billion in the USA.
10,000 aortic valve replacement for AI annually in the US alone
Target Market: 15-20% of aortic valve pathologies (replacement of open-heart surgery) *
CUSPA's initial target market are patients with moderate- severe AI. Pipeline development will target patients with MR, and TR.
20K = 0.5B
The CUSPER® device - An artificial cusp with a grasper which can be attached to one of the native valve cusps. The CUSPER is designed to compensate for cusps inadequate coaptation, effectively eliminating the regurgitant orifice while maintaining normal valve function. Although it requires normal cusp motion, the CUSPER addresses insufficiency of all four heart valves. The relatively small dimensions of the implant enable it to be delivered percutaneously via transcatheter approach with a low-profile delivery system, causing less trauma and allowing quick recovery.
- Preserves native valve motion
- Addresses all valves
- Minimally invasive
- Low-profile delivery systemsps.
- Targeting a huge unmet clinical need in cardiology that continues to be an early adoption market for new technologies and products.
- Intensive acquisition activity, first mover companies acquired by healthcare giants.
- CUSPA has begun opreations and received funding from the Israel innovation authority as part of NGT3 technology incubator.
Ariel Weigler, M.Sc., CEO - Mr. Weigler brings experience in R&D efforts, project management and team leadership in the medical-device industry.
Mr. Weigler has experience with multi-disciplinary medical device development including scanners and new technology imaging equipment. Mr. Weigler holds a B.Sc and M.Sc in biomedical engineering from the Technion. Israeli institute of technology.
Yair Feld MD, Ph.D, Founder, Director - Dr. Feld is interventional cardiologist with over 15 years of entrepreneurship and clinical research. Founder of CorAssist Cardiovascular, Nephera, Paragate medical and ProArc. Dr. Feld holds BSc in Physics, TAU, MD and PhD in Physiology, Biophysics from the Technion.
Ofer Pillar, M.Sc, MBA, Industry expert - An experienced entrepreneur for the past 30 years has been involved in the establishment and management of several medical devices / biotech start-up companies. VP Business Development Gyrus-ACMI (a multimillion public company acquired by Olympus for $2.1B) director of several medical device companies and Chairman of the investment committee of NGT3 fund and incubator.
Zohar Gendler, M.Sc , Chairman of the board - CEO & Managing Partner of NGT3 VC. Former CEO of BetaO2 and the Technion Entrepreneurial Incubator. Led the establishment and investment in more than 50 companies, such as Prolor Biotech (sold to OPKO, for $480M), Mazor (sold to Medtronic, $1.6B), Corindus (sold to Siemens, $1.1B,), ReWalk (NASDAQ: RWLK, and many others.
Contact Us :
Ariel Weigler - CEO
Mobile : +972-54-2231121
Fax : +972-4-6098611
E-mail : email@example.com
*A Comprehensive Guide to The U.S. TAVR Market: Looking Ahead. MED DEVICE ONLINE